Renal Business Today - Pharmaceuticals

FDA Updates Vytorin Label After CKD Study

WHITEHOUSE STATION, N.J.—The U.S. Food and Drug Administration (FDA) has approved an updated label for Merck's cholesterol drug Vytorin following results from the Study of Heart and Renal Protection (SHARP) in Patients With Moderate to Severe Chronic Kidney Disease. ...More

3 weeks ago

Posted in News, Clinical & Pharma

Hospira Starts Phase 3 of Biosimilar EPO Study

LAKE FOREST, Ill.—Hospira said Jan. 10 that it has started enrollment of the first patient in a Phase 3 U.S. clinical program for its biosimilar erythropoietin (EPO). ...More

January 10, 2012

Posted in News, Clinical & Pharma

KAI Starts Phase 2 Study of CKD-MBD Drug

SOUTH SAN FRANCISCO, Calif.— KAI Pharmaceuticals Inc. has started patient enrollment in the second phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) in hemodialysis patients ...More

January 6, 2012

Posted in News

WASHINGTON— Two seemingly similar blood pressure-lowering drugs have different effects on the heart health of dialysis patients, according to a study published online in the Journal of the American Society Nephrology (JASN). ...More

December 8, 2011

Posted in News, Clinical & Pharma

AlloCure Drug Could Help Treat AKI

BURLINGTON, Mass.—New clinical data suggest that a novel therapy under development by AlloCure could offer effective treatment for patients suffering from acute kidney injury (AKI). ...More

November 16, 2011

Posted in News, Clinical & Pharma

FDA Recommends Vytorin Approval in CKD Patients

WHITEHOUSE STATION, N.J.— Merck announced Nov. 2 that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously voted to recommend approval of Merck's Vytorin for use in patients with pre-dialysis chronic kidney ...More

November 2, 2011

Posted in News

Researchers Find New Way to Make Heparin

TROY, N.Y.—Researchers have discovered an entirely new process to manufacture ultra-low molecular weight heparin, according to a study in the Oct. 28 issue of Science. ...More

November 1, 2011

Posted in News, Clinical & Pharma

Promising Kidney Drug Fails in Large Clinical Trial

WASHINGTON—What was hoped to be a promising new drug to protect the kidneys has failed to benefit diabetes patients with kidney disease, according to a study appearing online Oct. 27 in the Journal of the American Society Nephrology (JASN). ...More

October 27, 2011

Posted in News, Clinical & Pharma

Abbott to Separate into Two Companies

ABBOTT PARK, Ill.—Abbott announced its plans to separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. ...More

October 20, 2011

Posted in News, Business

Researchers Uncover Cause of Hypertension From Antirejection Drugs

PORTLAND, Ore.—Researchers have discovered the process that could be causing side effects from antirejection transplant drugs, according to a study in Nature Medici ...More

October 10, 2011

Posted in News, Clinical & Pharma

Computers & Software	Consulting, Management...
Equipment & Services	Hemodialysis Supplies
Patient Services	More Options...

Pharmaceuticals

Mobile Health Snaps

Galleries

Most Popular Articles

Buyer's Guide

Resources

Free Email Updates

featured links

First Name	Last Name
E-Mail